0746 GMT - Novartis's significant profit and sales beat could close the gap between its mid-term growth guidance that is clearly above market's expectations, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's key drugs overall exceeded consensus with heart drug Entresto its best-selling medicine, despite prostate-cancer drug Pluvicto being shy of consensus, the analyst says. "This quarterly (and annual) results add on to a continuous streak of results where Novartis beats their own and the market's expectations," he said. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 31, 2025 02:46 ET (07:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。